Repurposing therapies in junctional epidermolysis bullosa: ivermectin may influence RNA splicing and improve functional protein expression

Clinical images of subject patient's lower limbs demonstrating improved wound re-epithelialisation with continued oral ivermectin therapy from February 2021 (Fig. 1), after four months of therapy in June 2021 (Fig. 2), and after one year of therapy in April 2022 (Fig. 3).